Silence Therapeutics (SLN)

Sector:

Pharma and Biotech

Index:

FTSE AIM 50

552.00p
   
  • Change Today:
      8.00p
  • 52 Week High: 649.00
  • 52 Week Low: 339.00
  • Currency: UK Pounds
  • Shares Issued: 89.74m
  • Volume: 57,575
  • Market Cap: £495.34m
  • RiskGrade: 177

Silence Therapeutics reveals positive data from SLN124 study

By Josh White

Date: Wednesday 19 May 2021

LONDON (ShareCast) - (Sharecast News) - Silence Therapeutics announced positive topline data from the 'GEMINI' phase 1 study of its wholly-owned product candidate 'SLN124' in healthy volunteers on Wednesday.
The AIM-traded firm said SLN124, a short interfering ribonucleic acid 'siRNA' which targets TMPRSS6, was in development for the treatment of iron-loading anemia conditions, thalassemia and myelodysplastic syndrome (MDS).

It said the GEMINI phase 1, randomised, double-blind, placebo-controlled, single-ascending dose study evaluated the safety and tolerability of SLN124 in 24 healthy volunteers, with 18 taking an active dose and six receiving placebo.

Pharmacokinetic parameters and pharmacodynamic biomarkers of iron metabolism were also measured to assess reduction in iron.

Initial data from the study showed all doses of SLN124 were generally well-tolerated, with no serious or severe treatment emergent adverse events, or adverse events leading to withdrawal.

The company said treatment emergent adverse events did not appear to be dose dependent, adding that the majority were mild, including transient injection site reactions which resolved without intervention.

Notably, up to an approximate four-fold increase in average hepcidin and a 50% reduction in plasma iron levels were also observed after a single dose of SLN124.

Effects on hepcidin and iron appeared to be dose dependent, and were still observed at the end of the eight-week study at all dose levels, indicating a sustained and long duration of action.

Silence said the clinical data supported preclinical findings which demonstrated SLN124 effectively improved red blood cell production and reduced anemia by increasing levels of hepcidin, which is a key natural regulator of iron balance and distribution in the body.

The company said it expected to measure red blood cell production and effects on anemia in the ongoing 'GEMINI II' phase 1 study of SLN124 in people with thalassemia and MDS, who, unlike healthy volunteers, had significantly elevated iron levels.

"These data represent the first clinical data from our 'mRNAi GOLD' platform and underscore the promising potential for our technology to deliver precision medicines," said president and chief executive officer Mark Rothera.

"We look forward to further data in patients anticipated from both of our wholly owned clinical programmes later this year - the GEMINI II study of SLN124 for iron-loading anemia conditions, and the APOLLO study of SLN360 for cardiovascular disease due to high lipoprotein(a)."

Silence said it expected to present full data from the GEMINI phase 1 study at an "appropriate scientific meeting" later in the year.

In addition, it said it was planning to report data from the single-ascending dose portion of the ongoing GEMINI II phase 1 study in the second half of the year.

SLN124 has orphan drug designation for both conditions, and rare pediatric disease designation for beta thalassemia.

At 0920 BST, shares in Silence Therapeutics were up 1.45% at 630p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

SLN Market Data

Currency UK Pounds
Share Price 552.00p
Change Today 8.00p
% Change 1.47 %
52 Week High 649.00
52 Week Low 339.00
Volume 57,575
Shares Issued 89.74m
Market Cap £495.34m
RiskGrade 177

SLN Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
43.56% below the market average43.56% below the market average43.56% below the market average43.56% below the market average43.56% below the market average
56% below the sector average56% below the sector average56% below the sector average56% below the sector average56% below the sector average
Price Trend
20.61% above the market average20.61% above the market average20.61% above the market average20.61% above the market average20.61% above the market average
25.81% above the sector average25.81% above the sector average25.81% above the sector average25.81% above the sector average25.81% above the sector average
Income Not Available
Growth
25.71% above the market average25.71% above the market average25.71% above the market average25.71% above the market average25.71% above the market average
22.22% above the sector average22.22% above the sector average22.22% above the sector average22.22% above the sector average22.22% above the sector average

What The Brokers Say

Strong Buy 4
Buy 0
Neutral 1
Sell 0
Strong Sell 0
Total 5
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

SLN Dividends

No dividends found

Trades for 20-Sep-2021

Time Volume / Share Price
16:35 9,504 @ 552.00p
16:29 10 @ 552.00p
16:29 8 @ 552.00p
16:29 7 @ 552.00p
16:28 500 @ 547.00p

Top of Page